The National Institute for Health and Care Excellence (NICE) finalized its decision not to recommend coverage of Roche's Ocrevus (ocrelizumab)...
Genentech, a member of the Roche Group announced new Ocrevus (ocrelizumab) data in relapsing and primary progressive multiple sclerosis (MS)...
Genentech, a member of the Roche Group announced that the Phase III OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with relapsing forms of MS or primary progressive MS (RMS or PPMS)
The National Institute for Health and Care Excellence (NICE) in its draft guidance has rejected Ocrevus (ocrelizumab) from Roche, as...
The National Institute for Health and Care Excellence (NICE) has recommended that Ocrevus (ocrelizumab) from Roche can be prescribed for...
Genentech/Roche announced new Ocrevus (ocrelizumab) analyses supporting its significant benefit on disease progression in early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS) as well as demonstrating high persistence and strong adherence to twice-yearly (six-monthly) dosing.
Genentech, a member of the Roche Group announced that new Ocrevus (ocrelizumab) data will be presented at the 34th Congress...
Genentech/Roche announced a higher-dose Phase III clinical trial program for Ocrevus (ocrelizumab) and a distinct Ocrevus trial specifically to support African-American and Hispanic- and Latin-American patients with MS.
Genentech, a member of the Roche Group, announced that new Ocrevus (ocrelizumab) data were presented at the 70th American Academy...
-Genentech has announced that new Ocrevus (ocrelizumab) data will be presented at the 4th Congress of the European Academy of...